<DOC>
	<DOCNO>NCT02343081</DOCNO>
	<brief_summary>The purpose crossover , single-dose , bioequivalence study compare rate extent absorption Temozolomide administration study product ( Dralitem® , Monte Verde S.A. ) reference product ( Temodal® , Schering Plough ) primary Central Nervous System patient .</brief_summary>
	<brief_title>Bioequivalence Study Temozolomide Patients With Primary Tumors Central Nervous System</brief_title>
	<detailed_description>Prospective , randomize , two-period , two treatment , two-way crossover bioequivalence study two Temozolomide oral formulation ( Dralitem vs. Temodal ) , primary Central Nervous System tumor patient fast condition . Open label patient investigator blind bioanalytical clinical laboratory . Study plan : day -21 0 ( Recruitment period ) ; day 1 5 ( Treatment period ) ; day 6 21 ( Safety surveillance period ) . Sample size : 24 patient randomize . The patient administer Temozolomide 200 mg/m2 first two day ( Dralitem ) treatment cycle . They admit study clinical site even day 2 . In morning day 3 randomize two group equal size . According assigned random number , subject receive single oral dose Temozolomide 200mg/m2 either Monte Verde Sociedad Anónima ( SA ) product ( Dralitem ) Schering-Plough product ( Temodal ) . The single dose 200 mg/m2 reach three different Temozolomide capsule strength : 20 , 100 250 mg . Drugs administer 200-240 ml water semi-sitting upright position . The following day ( day 4 ) subject receive oral dose Temozolomide 200 mg/m2 product receive day . On day 3 4 drug administration , blood sample obtain pharmacokinetic evaluation . The patient discharge clinical site day 4 completion sample pharmacokinetic analysis . On day 5 , patient receive Temozolomide 200 mg/m2 ( Dralitem ) . On day 3 4 , sample venous blood withdrawn forearm vein volunteer follow time point : 0 ( pre-dose ) 0.25 , 0.5 , 0.75 , 1.0 , 1.25 , 1.5 , 1.75 , 2.0 , 2.5 , 3.0 , 4.0 , 6.0 , 8.0 , 10.0 hour post-dose period administration . The washout period treatment arm 10 hour , day 3 4 . Samples process accord validate method MANA ( Método Analítico ) - PLB ( Proyecto Laboratorio Bioanalítico ) 004 - TEM ( Temozolomide ) - 01/01 . Measurement plasma concentration Temozolomide perform use High Performance Liquid Chromatography ( HPLC ) follow detection tandem mass spectrometry ( MS / MS ) . The area curve ( AUC ) Cmax level drug vs. time obtain subject . The result value logarithmic transformation parameter use statistical comparison ( mixed effect ANOVA ) . The limit 90 % confidence interval ratio log transform pharmacokinetic parameter calculate . Bioequivalence criterion : calculate confidence interval within acceptance range 80.00 125.00 .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Male female patient primary malignant tumor central nervous system ( CNS ) exclude subject primary CNS lymphoma . 2 . Age &gt; 21 year . 3 . There gap two week last surgery and/or radiotherapy procedure day randomization . If procedure intrabdominal , gap four week . 4 . Patients neutrophils &gt; 1.5 x 109 / L platelet &gt; 100 x 109 / L. 5 . Signed write informed consent participation trial . 1 . Known hypersensitivity Temozolomide ingredient pharmaceutical formulation . 2 . Any situation ( eg . vomit ) may interfere absorption product study . 3 . Chemotherapy biological therapy within four week prior administer product study . 4 . Patients experience symptom toxicity prior antineoplastic therapy upon administration product study . 5 . Participation clinical research study 90 day start study . 6 . History alcohol drug abuse . 7 . History severe allergic reaction type antigen . 8 . History gastrointestinal surgery ( except uncomplicated appendectomy , least three month old ) . 9 . Patients whose clinical status would affect safety product study interfere pharmacokinetic evaluation , discretion investigator . 10 . Pregnant woman woman plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>brain neoplasm</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>temozolomide</keyword>
</DOC>